Replies to post #16037 on Enzolytics Inc (ENZC)

[MIKEY501]

Somoene just got caught losing all their shares at .0005 lol

So easy to trick people

$ENZC

[MIKEY501]

Lets go Juan lets finish off these .0006s and get a chase going here!

$ENZC

[MIKEY501]

Gooood morning ENZC

[MIKEY501]

Top of the morning everyone

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[ZipCash]

Excelent DD bro PennyLand in the future for us

go enzc $$$$$$$$$$$$$$$

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

ENZC 20M ASK SMACK!

BOOM sounds like were close to showtime now.

$ENZC

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

Confirmed 1.5 billion AS with State of Delaware

Authorized Shares 1,500,000,000 04/30/2020
Outstanding Shares 1,447,966,662 04/30/2020
Restricted 738,839,585 04/30/2020
Unrestricted (FLOAT) 709,127,077 04/30/2020

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

Nice big ask smacks into the close yesterday. Lets see if we get some traction today.

$ENZC

[MIKEY501]

JUAN...need ask smacks...ENZC.

[forgiveness7x7]

RISK/REWARD, picked me up 3 mil@.0007 on high volume, could be real good here

[ZipCash]

Awesome call here BigJuan ! this is just starting to move north

looking for a Coppertown here with enzc

[MIKEY501]

Fantastic day here ENZC $$$$$$$$$$$$$$

[OptimusPrime555]

STOP sign on this stock!!!

Proof: https://www.otcmarkets.com/stock/ENZC/quote

[MIKEY501]

A couple nice ask smacks to open the day.

$ENZC

[brezlin]

I’m thinking after looking back at old volume here, that there could be hundreds of millions of shares out there .... naked stuff... most of these pennies that slowly grind into the ground are perfect targets because when they go BK, nobody has to cover, all profit... perfect hit! But now we know this one is going to market soon, have distribution in EU and Asia ALREADY set up and working on board member selections which is something you NEVER DO if you’re just going to stay a tiny pinkie.... They know how big this could be and are preparing for a fast, huge growth imo.... All we need is filings and a few more eyes on the stock and the climb will be epic!

Cover now or pay a lot more later....

Watch em start coming out of the woodwork over the next couple weeks.... every comment negative imaginable we’ll be seeing... mark this post!

[MIKEY501]

ENZC .0006 firing off again. Lets get the upticks started already.

$ENZC

[MIKEY501]

Bidders coming in ENZC

[MIKEY501]

Lets get the show started Juan!

$ENZC

$$$$$$$$$$$

[MIKEY501]

Bids building up ENZC $$$

[macdwatcher1]

Hello bigjuan. Can u try and post the current share structure for ENZC. You did it before forvthis stock not to long ago. About two weeks ago this stock was hair triggered. level ZII was very very thin after .0008. I’m still lock n loaded. The company should be making an earnest effort on becoming current with needed filings and more importantly this company should NZOT bein filution mode

[MIKEY501]

ENZC nice block ask smack.

$ENZC

[MIKEY501]

Are we working on those .0005 today Juan?

$ENZC

[MIKEY501]

Ask thinned out some more today. Are we ready?

$ENZC
#FREEJUAN

[MIKEY501]

ENZC another 15M ask smack to open the day. Super thin now.

$ENZC

[MIKEY501]

Here we go now only 14M left.

$ENZC

[MIKEY501]

ENZC absolutely rocking today!

$ENZC

[MIKEY501]

ENZC looking fantastic Juanito!

$ENZC

[MIKEY501]

ENZC .0006 starting to clear less than 10M left.

$ENZC

[MIKEY501]

ENZC Updated DD

PATENT VALUE PROJECTED PATENT VALUATION Predicted Patent Value: $5,203,874.67 https://enzolytics.com/patent

News below is legit per 8k also released. CEO confirms he is working on getting company current....READ BELOW

https://www.otcmarkets.com/filing/html?id=14076248&guid=Y24HUK4N_tD88th

PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.

The immediate goals include:

- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF

As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe. The company has made updates to its corporate website, www.enzolytics.com, and will continue to do so to provide further information to our shareholders.

[MIKEY501]

ENZC news out